What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Salud y medicinaOne-Off10m
Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptableAviso de calidad de datosDatos de la fuente degradados
Datos del 26 oct 2026, 1:00 UTC · política pm-quality-4
Pronóstico comunitario actual60-69% 25.6%Líder entre 7 opciones
Pronosticadores
14
Tipo de pregunta
multiple choice
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Cambio 7d
0.0 pts
Datos de mercado
Actualizado hace 8 horas
Desactualizado15 mar 24, 21:29 UTC2 sept 27, 6:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill the FDA approve any psychedelic substance for medical use this year?
KalshiHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketWill a pneumonic plague case be reported in the U.S. this year?
KalshiReglas
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.